ENhancing Exercise With LIGHT to Improve Functioning in PAD

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Peripheral Artery Disease, Peripheral Vascular Disease, Aging, Walking, Difficulty

In brief

The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).

Key facts

Study ID: NCT06399900
Run by: Northwestern University
People needed: 32
Starts: 2024-08-12
Expected to finish: 2027-01-31
Last updated by the study team: 2026-04-15

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:
An ABI <= 0.90 at baseline.
Vascular lab evidence of PAD (such as a toe brachial pressure <= 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.
An ABI of >0.90 and <= 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.

You may not qualify if…

Above- or below-knee amputation
Critical limb ischemia defined as an ABI <0.40 with symptoms of rest pain
Wheelchair confinement or requiring a walker to ambulate
Walking is limited by a symptom other than PAD
Current foot ulcer on bottom of foot
Failure to successfully complete the study run-in
Planned major surgery, coronary or leg revascularization during the next four months
Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent, unless the cancer is located in the lower extremities. Participants who require oxygen only at night may still qualify.]
Mini-Mental Status Examination (MMSE) score < 23
Non-English speaking
Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
Visual impairment that limits walking ability.
Six-minute walk distance of <400 feet or >1700 feet.
Participation in a supervised treadmill exercise program or a cardiac rehabilitation program in previous three months or planning to begin a supervised treadmill exercise program or a cardiac rehabilitation program in the next five months.
Unwilling to avoid red light therapy outside of study participation.
Baseline blood pressure <100/45.
In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Where it is running

Northwestern University — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.